Nervgen Pharma Corp. NGEN
Annual
Quarterly
No annual revenue total was found in NERVGEN PHARMA CORP.'s SEC filings.
Nervgen Pharma Corp. (NGEN) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
79.65M
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- NGEN (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Vancouver
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1751912
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K/A | Form 6-k/a | Oct 16, 2026 | Aug 13, 2026 |
| 40-F/A | Amended annual report (Canadian issuer) | Oct 16, 2026 | Dec 31, 2025 |
| 6-K | Current report (foreign issuer) | Sep 25, 2026 | Sep 25, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 24, 2026 |
| 6-K | Current report (foreign issuer) | Aug 13, 2026 | Aug 13, 2026 |
| 6-K | Current report (foreign issuer) | Jul 2, 2026 | Jul 2, 2026 |
All 41 Nervgen Pharma Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.